P/E ratio for Rockwell Medical (RMTI)
P/E ratio as of April 2024 (TTM): -1.65
According to Rockwell Medical 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.64773. At the end of 2022 the company had a P/E ratio of -0.5401.
P/E ratio history for Rockwell Medical from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.5401 | -54.13% |
| 2021 | -1.18 | -52.2% |
| 2020 | -2.46 | -43.46% |
| 2019 | -4.36 | 19.53% |
| 2018 | -3.65 | -68.06% |
| 2017 | -11.4 | -30.31% |
| 2016 | -16.4 | -53.63% |
| 2015 | -35.3 | 82.05% |
| 2014 | -19.4 | 206.55% |
| 2013 | -6.33 | 107.5% |
| 2012 | -3.05 | -56.44% |
| 2011 | -7.00 | -86.71% |
| 2010 | -52.7 | 153.4% |
| 2009 | -20.8 | 182.74% |
| 2008 | -7.35 | -67.24% |
| 2007 | -22.4 | 25.88% |
| 2006 | -17.8 | -103.99% |
| 2005 | 447 | 325.71% |
| 2004 | 105 | -98.96% |
| 2003 | > 1000 | -205454.94% |
| 2002 | -4.92 | -12.2% |
| 2001 | -5.60 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | 36.2 | -2,295.26% | 🇺🇸 USA |
 Baxter BAX | 7.85 | -576.15% | 🇺🇸 USA |
 Mesa Laboratories MLAB | 302 | -18,455.01% | 🇺🇸 USA |
 ICU Medical
ICUI | -47.0 | 2,754.81% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.